OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lin on Treatment Updates in CAR T-Cell Therapy in Myeloma

April 21st 2022

Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

Dr. Edington on the Utilization of TIL Therapy in Melanoma

April 21st 2022

Howard D. Edington, MD, discusses the utilization of tumor-infiltrating lymphocyte therapy in melanoma.

Dr. Fausel on the Evolution of Genomic Testing in Cancer Care

April 21st 2022

Christopher A. Fausel, PharmD, MHA, BCOP, discusses how genetic sequencing has played a growing role in cancer care.

Dr. Miller on the Current Treatment Landscape of Ovarian Cancer

April 19th 2022

Eirwen M. Miller, MD, discusses the current treatment landscape of ovarian cancer.

Dr. Moon on the Utilization of Relatlimab Plus Nivolumab in Metastatic Melanoma

April 19th 2022

Helen Heng-Shan Moon, MD, discusses the utilization of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

Dr. Barzi on Combination Regorafenib and Pembrolizumab in MSS CRC

April 19th 2022

Afsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.

Dr. Cohen on Potential With CAR T-Cell Therapy in Medullary Thyroid Cancer

April 19th 2022

Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).

GFRα4 May Represent a Unique Therapeutic Target in Medullary Thyroid Cancer

April 19th 2022

Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).

Dr. Edington on the Importance of Prevention Strategies in Melanoma

April 19th 2022

Howard D. Edington, MD, discusses the importance of prevention strategies in melanoma.

Dr. Cusnir on the Most Effective Uses of Chemotherapy Treatment in CRC

April 19th 2022

Mike Cusnir, MD, discusses the most effective uses of chemotherapy in colorectal cancer.

Dr. Cohen on Diversifying the Patient Population for a Clinical Trial in Medullary Thyroid Cancer

April 19th 2022

Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).

Dr Cabanillas on Delivering the "Right" Surgery to Patients With MTC

April 19th 2022

Maria E. Cabanillas, MD, an oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses how to deliver the optimal surgical approach to patients with medullary thyroid cancer.

Dr. Choueiri on Next Steps for Pembrolizumab in RCC

April 19th 2022

Toni Choueiri, MD, discusses the next steps for the evaluation of pembrolizumab in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma.

Dr Cabanillas on Current Systemic Treatments in MTC and the Potential for PRRT

April 19th 2022

Maria E. Cabanillas, MD, oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses current systemic treatments in medullary thyroid cancer, along with the potential for peptide receptor radionuclide therapy.

Dr. Oberstein on the Utilization of CtDNA in Metastatic CRC

April 18th 2022

Paul E. Oberstein, MD, discusses the utilization of ctDNA in metastatic colorectal cancer.

Dr. Tawbi on the Utilization of Relatlimab and Nivolumab in Metastatic Melanoma

April 18th 2022

Hussein A. Tawbi, MD, PhD, discusses the utilization of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Dr. Ornstein on the Efficacy of Neoadjuvant Avelumab and Axitinib in RCC

April 18th 2022

Moshe Ornstein, MD, MA, discusses the efficacy findings from a phase 2 trial examining neoadjuvant avelumab and axitinib in renal cell carcinoma.

Dr. Pollyea on the Role of Maintenance Therapy in AML

April 14th 2022

Dan Pollyea, MD, MS, discusses the current role of maintenance therapy in patients with acute myeloid leukemia who are unfit for intensive chemotherapy.

Dr. Carraway on Next-Generation Sequencing in AML

April 14th 2022

Hetty Carraway, MD, discusses important considerations for the future of acute myeloid leukemia regarding mutations and next-generation sequencing.

Dr. Maron on HER2-Positive Tumors in Esophageal Gastric Cancers

April 14th 2022

Steven Maron, MD, MSc, discusses HER2-positive tumors in esophageal gastric cancers.

NEXT PAGE
PREVIOUS PAGE